MedTrace Logo

Bioavailability Study of Metronidazole Capsules Under Fasting Conditions

NCT01380509 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2011-06-27

No results posted yet for this study

Summary

The purpose of this study is to compare the single-dose Bioavailability of Kali and G.D. Searle, Inc.

Conditions

  • To Determine the Bioequivalence Study Under Fasting

Interventions

DRUG

Metronidazole

Capsules, single-dose, fasting

DRUG

Flagyl

Capsules, single-dose, fasting

Sponsors & Collaborators

  • Algorithme Pharma Inc

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Christian Sicard, M.D · Algotithme Pharma Inc

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-08-31
Primary Completion
2002-09-30
Completion
2002-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380509 on ClinicalTrials.gov